In a groundbreaking verdict that could reshape pharmaceutical antitrust litigation, a U.S. jury has found Japanese pharmaceutical giant Takeda liable…
Read More
Global Healthcare Giants Unite: GHO Capital and CBC Group Forge Largest Dedicated Investment Manager with $21 Billion AUM
Two prominent forces in specialized healthcare investment, Global Healthcare Opportunities (GHO) and CBC Group, have announced a groundbreaking merger to…
Read More
Regeneron Pharmaceuticals and Parabilis Medicines Forge Landmark $2.32 Billion Collaboration to Pioneer a New Era of Intracellular Therapies
Regeneron Pharmaceuticals has announced a monumental research collaboration with Parabilis Medicines, a deal valued at an impressive $2.32 billion. This…
Read More
Insilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’
In a landmark move poised to reshape the landscape of pharmaceutical innovation, Insilico Medicine, a pioneer in artificial intelligence (AI)-driven…
Read More
Fake testimonials, no pharmacy and an FDA warning: how Medvi built a $1.8 billion telehealth company in the gaps between regulators
The recent profile of Medvi by The New York Times earlier this month highlighted the company as a prime example…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, currently buoyed by the explosive success of its GLP-1 franchise, has announced its intent to acquire…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
The majority of these high-value collaborations, roughly half, involved firms of U.S. origin, predominantly structured as mergers and acquisitions (M&A).…
Read More
Isomorphic Labs Secures $2.1 Billion in Series B Funding to Accelerate AI-Driven Drug Discovery and Development
AI drug design and development firm Isomorphic Labs has successfully closed a significant $2.1 billion Series B funding round, marking…
Read More
Bristol Myers Squibb and Hengrui Pharma Forge Landmark $15.2 Billion Oncology and Immunology Collaboration
Bristol Myers Squibb (BMS) and Chinese biopharmaceutical giant Hengrui Pharma have announced a monumental licensing and collaboration agreement, potentially valued…
Read More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion to Bolster Rare Disease and Brain Health Portfolio
Angelini Pharma, a prominent player in the pharmaceutical sector, has announced a definitive agreement to acquire Catalyst Pharmaceuticals for an…
Read MoreYOU MAY HAVE MISSED
